GeoVax Operating Margin from 2010 to 2024

GOVXW Stock  USD 0.12  0.02  14.29%   
GeoVax Labs Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin is likely to outpace its year average in 2024.
Check GeoVax Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeoVax Labs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 70.5 K, Interest Expense of 48.6 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 324, Dividend Yield of 0.0 or PTB Ratio of 2.27. GeoVax financial statements analysis is a perfect complement when working with GeoVax Labs Valuation or Volatility modules.
  
Check out the analysis of GeoVax Labs Correlation against competitors.
For more information on how to buy GeoVax Stock please use our How to Invest in GeoVax Labs guide.

Latest GeoVax Labs' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of GeoVax Labs over the last few years. It is GeoVax Labs' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeoVax Labs' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (16.84) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

GeoVax Operating Margin Regression Statistics

Arithmetic Mean(43.17)
Coefficient Of Variation(175.25)
Mean Deviation58.35
Median(3.10)
Standard Deviation75.66
Sample Variance5,725
Range199
R-Value(0.73)
Mean Square Error2,875
R-Squared0.53
Significance0
Slope(12.36)
Total Sum of Squares80,151

GeoVax Operating Margin History

2024 -189.22
2023 -199.18
2022 -173.2
2021 -48.69
2020 -1.55
2018 -2.66
2017 -2.02

About GeoVax Labs Financial Statements

GeoVax Labs investors use historical fundamental indicators, such as GeoVax Labs' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in GeoVax Labs. Please read more on our technical analysis and fundamental analysis pages.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia. Geovax Labs is traded on NASDAQ Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for GeoVax Stock Analysis

When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.